Lantheus (NASDAQ:LNTH) Posts Earnings Results, Misses Estimates By $0.23 EPS

Lantheus (NASDAQ:LNTH - Get Free Report) released its earnings results on Thursday. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23), Zacks reports. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million.

Lantheus Trading Up 2.5 %

LNTH stock traded up $2.33 during trading on Friday, hitting $93.82. The company had a trading volume of 987,849 shares, compared to its average volume of 888,396. The firm has a market capitalization of $6.52 billion, a price-to-earnings ratio of 15.61 and a beta of 0.44. The business has a 50 day moving average of $89.89 and a 200 day moving average of $96.73. Lantheus has a fifty-two week low of $56.44 and a fifty-two week high of $126.89.

Analyst Ratings Changes

Several analysts have weighed in on the stock. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price for the company. JMP Securities reissued a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial boosted their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday. Finally, StockNews.com downgraded shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $132.86.

Remove Ads

Insider Buying and Selling

In related news, Director James H. Thrall sold 1,000 shares of the company's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company's stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.